Vaccine chief Vinay Prasad's sudden departure from the FDA may be good for select biotech companies and deals, but the agency's revolving door will only extend uncertainty for the broader sector.
Why it matters: That uncertainty, coupled with other macro challenges, could further depress biotech dealmaking.
